Nectar Lifescience
Healthcare
NECLIFE NSE
₹10.26 No trade today
- P/E
- Not meaningful: loss-making over the last twelve months
Close 4 Nov 2026 ₹10.26 −3.75 −26.8% 1Y
Start ₹14.01
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 0.05%
- Debt to Equity
- 0.00
- EPS (TTM)
- −₹11.50
- Book Value
- ₹29.97
- Market Cap
- —
- P/E (TTM)
- Not meaningful: loss-making over the last twelve months
- P/B
- 0.34
- ROE
- −31.30%
- Dividend Yield
- 0.00%
- EBITDA
- −₹51.40 Cr
- 52W High
- ₹22.40
- 52W Low
- ₹9.30
- Volume
- 0
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Nectar Lifescience (this company) | ₹10.26 | — | ₹199 Cr | 0.34 | 0.00% | −31.30% | 0.05% | ₹2 Cr | −₹245 Cr |
| Median 8 companies | ₹1,587.70 | 38.81 | ₹1,25,337 Cr | 4.57 | 0.44% | 16.25% | 16.65% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
31 Poor
Data confidence 91/100
surveillance:ASM1
Category scores
- Quality
- 11
- Poor
- Returns, margins, earnings quality 22% weight
- Valuation
- 45
- Weak
- Cheap vs sector & own history 24% weight
- Growth
- 1
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 52
- Average
- Solvency, leverage, coverage 9% weight
- Momentum
- 24
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 53
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
3- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 0.35 times its book value
Weaknesses
4- Company has low interest coverage ratio.
- Company has a low return on equity of -12.3% over last 3 years.
- Contingent liabilities of Rs.269 Cr.
- Promoter holding has decreased over last 3 years: -3.96%
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 12 | 7 | 0 |
| Oscillators | Bearish | 2 | 7 | 0 |
| Moving Averages | Strong Bearish | 10 | 0 | 0 |
Oscillators
Bearish
Bearish
2
Neutral
7
Bullish
0
Overall
Strong Bearish
Bearish
12
Neutral
7
Bullish
0
Moving Averages
Strong Bearish
Bearish
10
Neutral
0
Bullish
0
Key readings
- RSI (14)
- 44.32
- Neutral
- MACD (12,26,9)
- −0.17
- Bearish
- SMA (50)
- 11.03
- Bearish
- SMA (200)
- 11.71
- Bearish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | −100.00% |
|---|---|
| 5Y | −100.00% |
| 3Y | −100.00% |
| 1Y | −100.00% |
| TTM | −81.82% |
Net profit
| 10Y | Turned to loss |
|---|---|
| 5Y | Loss widened by ₹220 Cr |
| 3Y | Loss widened by ₹269 Cr |
| 1Y | Loss widened by ₹179 Cr |
| TTM | Loss widened by ₹66 Cr |
Operating cash flow
| 10Y | Turned negative |
|---|---|
| 5Y | Turned negative |
| 3Y | Turned negative |
| 1Y | Turned negative |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | No sales |
|---|---|
| 5Y | No sales |
| 3Y | No sales |
| 1Y | No sales |
| TTM | Tiny sales |
Revenue by year
| Mar 2017 | ₹1,635 Cr |
|---|---|
| Mar 2018 | ₹1,874 Cr |
| Mar 2019 | ₹2,779 Cr |
| Mar 2020 | ₹2,363 Cr |
| Mar 2021 | ₹1,541 Cr |
| Mar 2022 | ₹1,665 Cr |
| Mar 2023 | ₹1,520 Cr |
| Mar 2024 | ₹1,682 Cr |
| Mar 2025 | ₹1,664 Cr |
| Mar 2026 | ₹0.00 Cr |
Net profit by year
| Mar 2017 | ₹55.00 Cr |
|---|---|
| Mar 2018 | ₹52.00 Cr |
| Mar 2019 | ₹48.00 Cr |
| Mar 2020 | ₹32.00 Cr |
| Mar 2021 | −₹73.00 Cr |
| Mar 2022 | ₹25.00 Cr |
| Mar 2023 | −₹24.00 Cr |
| Mar 2024 | ₹5.00 Cr |
| Mar 2025 | −₹114 Cr |
| Mar 2026 | −₹293 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 394 | 398 | 452 | 441 | 359 | 6 | 0 | 0 | 5 | 1 | 0 | 1 | 0 |
| Expenses | 359 | 371 | 410 | 393 | 319 | 6 | 0 | 0 | 6 | 0 | 2 | 59 | 28 |
| Operating Profit | 36 | 27 | 42 | 48 | 40 | −1 | 0 | 0 | −1 | 1 | −2 | −57 | −27 |
| OPM % | 9% | 7% | 9% | 11% | 11% | −10% | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | −16% | 77% | — | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. |
| Other Income | 0 | 11 | 0 | 1 | 1 | 7 | 8 | −130 | −62 | −176 | 35 | −24 | 3 |
| Interest | 18 | 21 | 25 | 24 | 20 | 0 | 0 | 0 | 0 | 0 | 30 | 6 | 0 |
| Depreciation | 15 | 15 | 15 | 15 | 15 | 0 | 0 | 0 | 1 | 0.2 | 0 | 0 | 0 |
| PBT | 3 | 2 | 2 | 11 | 5 | 5 | 8 | −130 | −64 | −176 | 3 | −88 | −24.62 |
| Tax % | 41% | 38% | 36% | 95% | 40% | −2% | 2% | 0% | −1% | 0% | −339% | −22% | −37% |
| Net Profit | 2 | 1 | 2 | 1 | 3 | 6 | 8 | −130 | −63 | −176 | 14 | −68 | −15 |
| EPS (₹) | 0.08 | 0.05 | 0.07 | 0.03 | 0.13 | 0.25 | 0.35 | −5.8 | −2.82 | −7.85 | 0.64 | −3.5 | −0.79 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,638 | 1,674 | 1,635 | 1,874 | 2,779 | 2,363 | 1,541 | 1,665 | 1,520 | 1,682 | 1,664 | 0 | 2 |
| Expenses | 1,371 | 1,436 | 1,411 | 1,638 | 2,514 | 2,143 | 1,432 | 1,507 | 1,467 | 1,530 | 1,694 | 8 | 88 |
| Operating Profit | 267 | 239 | 224 | 236 | 264 | 220 | 109 | 159 | 53 | 152 | −30 | −8 | −86 |
| OPM % | 16% | 14% | 14% | 13% | 10% | 9% | 7% | 10% | 3.5% | 9% | −1.8% | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. |
| Other Income | 20 | 6 | 23 | 6 | 6 | 4 | −22 | 11 | 43 | 15 | 5 | −279 | −162 |
| Interest | 126 | 123 | 117 | 115 | 148 | 126 | 112 | 79 | 79 | 87 | 75 | 36 | 36 |
| Depreciation | 77 | 57 | 62 | 64 | 63 | 61 | 60 | 57 | 59 | 61 | 62 | 0 | 0 |
| PBT | 85 | 64 | 67 | 63 | 59 | 37 | −85 | 34 | −42 | 18 | −162 | −323 | −285 |
| Tax % | 22% | 15% | 18% | 17% | 19% | 15% | −14% | 26% | −43% | 73% | −30% | −9% | — |
| Net Profit | 66 | 54 | 55 | 52 | 48 | 32 | −73 | 25 | −24 | 5 | −114 | −293 | −245 |
| EPS (₹) | 2.95 | 2.42 | 2.47 | 2.33 | 2.12 | 1.42 | −3.27 | 1.12 | −1.08 | 0.22 | −5.07 | −15.08 | −11.5 |
| Div. Payout % | 3% | 4% | 2% | 2% | 2% | 4% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 19 |
| Reserves | 936 | 932 | 984 | 1,036 | 1,083 | 1,114 | 1,040 | 1,065 | 1,042 | 1,047 | 934 | 563 |
| Borrowings | 925 | 962 | 878 | 955 | 903 | 779 | 903 | 860 | 754 | 636 | 582 | 0 |
| Other Liabilities | 628 | 640 | 696 | 710 | 696 | 718 | 423 | 443 | 371 | 486 | 509 | 39 |
| Total Liabilities | 2,510 | 2,556 | 2,581 | 2,724 | 2,705 | 2,633 | 2,388 | 2,391 | 2,189 | 2,191 | 2,047 | 622 |
| Fixed Assets | 934 | 906 | 881 | 852 | 825 | 785 | 772 | 723 | 662 | 643 | 633 | 105 |
| CWIP | 91 | 99 | 102 | 100 | 100 | 115 | 99 | 85 | 78 | 66 | 57 | 0 |
| Investments | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 13 |
| Other Assets | 1,485 | 1,551 | 1,597 | 1,771 | 1,780 | 1,733 | 1,517 | 1,582 | 1,449 | 1,482 | 1,357 | 504 |
| Total Assets | 2,510 | 2,556 | 2,581 | 2,724 | 2,705 | 2,633 | 2,388 | 2,391 | 2,189 | 2,191 | 2,047 | 622 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 144 | 169 | 199 | 65 | 239 | 285 | 21 | 95 | 134 | 225 | 169 | −349 |
| Investing | −60 | −77 | −18 | −29 | −26 | −33 | −29 | 17 | 52 | −17 | −42 | 1,208 |
| Financing | −61 | −89 | −204 | −40 | −201 | −252 | 11 | −119 | −186 | −205 | −128 | −767 |
| Net Cash Flow | 23 | 3 | −23 | −4 | 12 | 0 | 4 | −8 | 0 | 2 | −1 | 93 |
| Free Cash Flow | 64 | 87 | 174 | 32 | 204 | 249 | −10 | 110 | 183 | 195 | 126 | −341 |
| CFO/OP | 56 | 74 | 92 | 33 | 96 | 134 | 23 | 60 | 252 | 148 | −574 | 4,132 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 99 | 107 | 112 | 119 | 73 | 61 | 89 | 98 | 67 | 82 | 76 | — |
| Inventory Days | 253 | 260 | 270 | 226 | 151 | 192 | 185 | 197 | 212 | 215 | 184 | — |
| Days Payable | 146 | 154 | 167 | 142 | 80 | 104 | 108 | 112 | 100 | 127 | 117 | — |
| Cash Conversion Cycle | 207 | 213 | 215 | 203 | 145 | 150 | 166 | 182 | 179 | 170 | 143 | — |
| Working Capital Days | 40 | 41 | 45 | 67 | 46 | 53 | 6 | 73 | 77 | 63 | 43 | — |
| ROCE % | 11% | 10% | 10% | 9% | 10% | 8% | 3% | 5% | 0% | 6% | −5% | 0% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Nectar Lifescience insights
69 extracted metrics across FY11–FY27.
Documents
- 30 May 2026
- 2 Mar 2026
- 16 Jan 2026
- 16 Jul 2025
- 1 Jul 2025
- 25 Nov 2024
- General announcements 6 Oct 2026
Frequently Asked Questions about Nectar Lifescience
What does Nectar Lifescience Ltd do?
Incorporated in 1995, Nectar Lifesciences Ltd manufactures APIs and Formulations
Where is Nectar Lifescience Ltd (NECLIFE) listed?
Nectar Lifescience Ltd trades as NECLIFE on the NSE and under code 532649 on the BSE.
Which sector does Nectar Lifescience Ltd belong to?
Nectar Lifescience Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the 52-week high and low of Nectar Lifescience Ltd?
Over the last 52 weeks Nectar Lifescience Ltd has traded between ₹9.3 and ₹22.4 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Nectar Lifescience Ltd?
Nectar Lifescience Ltd reported a return on equity of -31.30%. Its debt-to-equity ratio is 0.00.
Company Information
Incorporated in 1995, Nectar Lifesciences Ltd manufactures APIs and Formulations
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/NECLIFE.md for Nectar Lifescience Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.